Current AstraZeneca Vice President Respiratory, Inflammation & Autoimmunity James Ward-Lilley will become CEO of Vectura Group as of October 1 2015. Vectura had previously announced that its current CEO, Chris Blackwell, will be stepping down at the end of June 2015.
Ward-Lilley, who has held a variety of roles at AstraZeneca over the past 28 years, commented, “I am delighted to have accepted the role of CEO of Vectura and to build on the already strong foundations that are in place. I am looking forward to driving the business forward and ensuring the company achieves its goal on becoming a speciality pharmaceutical company.”
.
Vectura Chairman Bruno Angelici said, “We are delighted that James is joining as CEO. His significant relevant experience in the respiratory market which he has gained within a major global pharmaceutical company will be a considerable asset for Vectura. James joins at an exciting and important time for Vectura and we are confident that the company will continue to grow from strength to strength under his leadership.”
Read the Vectura press release.
